Effect of Recombinant Interferon Alpha-2b on Metastatic Tumors
Author Information
Author(s): B. Biesmal, P.H.B. Willemsel, N.H. Mulder, R.C.J. Verschueren, I.P. Kema, H.W.A. de Bruijn, P.E. Postmus, D.Th. Sleijfer, E.G.E. de Vries
Primary Institution: University Hospital Groningen, The Netherlands
Hypothesis
Does recombinant human interferon alpha-2b improve outcomes in patients with metastatic apudomas?
Conclusion
Recombinant interferon alpha-2b showed beneficial effects in patients with progressive tumors without increasing neutralizing antibodies.
Supporting Evidence
- Two patients showed a reduction in tumor size.
- 80% of patients had stable disease.
- 60% of carcinoid patients with elevated urinary 5-HIAA levels had a biochemical partial response.
Takeaway
This study tested a medicine called interferon on patients with certain tumors, and it helped many feel better and showed some positive effects on their tumors.
Methodology
Patients with progressive malignant carcinoid tumors, islet cell tumors, or medullary thyroid carcinoma were treated with daily subcutaneous injections of recombinant human interferon alpha-2b.
Limitations
The study had a small sample size and was limited to specific tumor types.
Participant Demographics
{"median_age":58.5,"age_range":"36-79","male_female_ratio":"14/10"}
Want to read the original?
Access the complete publication on the publisher's website